Rheumatoid
arthritis is a disease that causes pain and inflammation in joints. It affects
individuals of all ages; however, the geriatric population is highly
susceptible to develop this disease. The symptoms of rheumatoid arthritis
include pain, stiffness, tender, and swelling of joints. Currently, no cure is
available for rheumatoid arthritis. However, certain drugs are used to
efficiently control the conditions of rheumatoid arthritis, which include
disease-modifying anti-rheumatic drugs (DMARDs), nonsteroidal anti-inflammatory
drugs (NSAIDs), corticosteroids, and uric acid drugs.
Request Sample
Report for More Insights: https://www.alliedmarketresearch.com/request-sample/3753
Impact of
COVID-19 Pandemic on Rheumatoid Arthritis Drugs Market (Pre and Post Analysis)
The World
Health Organization (WHO) on January 30, 2020 declared COVID-19 outbreak a
public health emergency of international concern. COVID-19 has affected around
210 countries across the globe. According to the Lancet Rheumatology 2020,
patients with rheumatoid arthritis who develop COVID-19 infection may be at
high risk for developing severe symptoms and additional complications. Some
DMARDs commonly used to treat rheumatoid arthritis, such as hydroxychloroquine
drug, are being investigated as potential therapy for COVID-19. Moreover, other
generally used therapies such as biologics targeting interleukin (IL)-6
(sarilumab, tocilizumab) and IL-1 (anakinra) are being assessed in patients
with COVID-19. Thus, COVID-19 infection uplifted growth opportunities for
manufacturers of rheumatoid arthritis drugs during the forecast period.
The global rheumatoid arthritis drugs market is segmented into drug class, route of
administration, sales channel, and region. Depending on drug class, the market
is categorized into disease-modifying anti-rheumatic drugs (DMARDs),
nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, uric acid
drugs, and others. By route of administration, it is segregated into oral and
parenteral. On the basis of sales channel, it is fragmented into
prescription-based drugs and over-the-counter drugs. Region wise, the market is
analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Asia-Pacific
presents lucrative opportunities for key players operating in the rheumatoid
arthritis drugs market, owing to the presence of large population base
susceptible to rheumatoid arthritis, increase in public awareness toward use
& benefits of these drugs, development of the R&D sector, rise in
healthcare reforms, and increase in adoption of rheumatoid arthritis drugs.
Moreover, increase in demand for DMARDs and rise in geriatric population
contribute toward growth of the market.
Key
Market Players
- Abbvie Inc.
- Amgen Inc.
- Bristol-Myers Squibb Company
- Eli Lilly And Company
- F. Hoffmann-La Roche Ltd.
- Johnson & Johnson
- Merck & Co., Inc.
- Novartis Ag (Sandoz)
- Pfizer Inc.
- UCB S.A.
Key
Benefits For Stakeholders
- In-depth analysis of the rheumatoid arthritis drugs market size along with the current trends and future estimations to elucidate the imminent investment pockets.
- Rheumatoid arthritis drugs market analysis from 2019 to 2027, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the rheumatoid arthritis drugs market.
- A comprehensive analysis of four regions is provided to determine the prevailing opportunities.
- The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook and market growth.
0 Comments